Summary of COVID-19 zavegepant studies

1. Amali et al., BHV3500-203: Phase 2/3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Zavegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen

47 patient zavegepant late treatment RCT: 168% higher mortality (p=0.4), 25% higher ICU admission (p=1), and 11% worse recovery (p=0.47).
RCT 47 hospitalized COVID-19 patients in the USA showing no significant differences with zavegepant treatment.
May 2024, NCT04346615, https://clinicaltrials.gov/study/NCT04346615, https://c19p.org/amali